LACTOLOGY FOUNDATION

This monograph summarizes lactation‑related toxicology for medicines classified in ATC group A07 “Antidiarrheals, intestinal anti‑inflammatory/anti‑infective agents”, with focus on maternal use during breastfeeding and potential effects in breastfed infants.wikipedia+1

Therapeutic group overview

ATC group A07 belongs to the alimentary tract and metabolism classes and comprises drugs acting mainly locally in the intestinal lumen to treat diarrhea, intestinal infections, and inflammatory bowel conditions.atccode+1
Subgroups include intestinal antiinfectives (A07A), intestinal adsorbents (A07B), electrolytes with carbohydrates (A07C), antipropulsives (A07D), intestinal anti‑inflammatory agents (A07E), antidiarrhoeal microorganisms (A07FA), and other antidiarrhoeals (A07XA).greenbook.nafdac+1

Pharmacological subgroups and representative agents

Intestinal antiinfectives (A07A) include locally acting antibiotics, sulfonamides, imidazole derivatives and other antiinfectives given orally to manage enterocolitis or intestinal infections.atcddd.fhi+2
Other subgroups comprise agents that reduce intestinal motility (e.g. loperamide, diphenoxylate, opium derivatives), adsorbents such as activated charcoal preparations, electrolyte–carbohydrate replacement solutions, probiotic microorganisms and locally acting anti‑inflammatory drugs for inflammatory bowel disease.atcddd.fhi+3

General pharmacokinetic and exposure considerations in lactation

Most A07 medicines are designed for local action in the gut with limited systemic absorption, which tends to reduce transfer into breast milk and infant exposure.atcddd.fhi+2
General lactation principles indicate that medicines with low oral bioavailability, high protein binding, short half‑life and high molecular weight, used at the lowest effective dose and for short durations, are less likely to cause clinically significant effects in breastfed infants.medsafe+1

Maternal benefits versus infant risks

Appropriate treatment of maternal diarrhea and intestinal inflammation helps maintain hydration, nutritional status, and overall health, which supports successful lactation.mayoclinic+1
For most medicines, the small quantities transferred into milk are unlikely to be harmful, but risk–benefit assessment is essential in premature, very young, or medically fragile infants where gastrointestinal or central nervous system adverse effects could be more pronounced.medsafe+1

Safety profile across A07 subgroups

Intestinal antiinfectives with minimal systemic absorption generally present low lactation risk, although systemic antibacterial therapy may be preferred when significant maternal infection is suspected, following standard breastfeeding‑compatible antibiotic guidance.atcddd.fhi+2
Antipropulsives (e.g. loperamide, diphenoxylate, opium derivatives) can reduce intestinal motility, and while maternal therapeutic doses are often compatible with breastfeeding, prolonged use or high doses may pose a theoretical risk of infant sedation, constipation, or ileus, especially in neonates.atcddd.fhi+2

Intestinal adsorbents such as activated charcoal are poorly absorbed and are unlikely to reach breast milk in significant amounts, so clinically meaningful exposure of the infant is not expected.atcddd.fhi+1
Electrolyte–carbohydrate solutions and probiotic microorganisms have minimal or no direct transfer into breast milk, and their main safety concerns relate to maternal tolerance and underlying disease rather than specific lactation toxicity.atccode+1

Potential adverse effects in breastfed infants

The most relevant potential infant adverse effects with A07 medicines include gastrointestinal symptoms (altered stool pattern, diarrhea or constipation, abdominal discomfort) and, with opioid‑related antipropulsives, possible central nervous system depression.mayoclinic+2
Clinicians should advise caregivers to monitor breastfed infants for changes in feeding, excessive somnolence, irritability, reduced responsiveness, or persistent gastrointestinal symptoms, and seek medical evaluation if these occur while the mother is treated with A07 drugs.medsafe+1

Clinical use recommendations in breastfeeding

In most cases, A07 medicines can be used during breastfeeding when clinically indicated, provided that the lowest effective dose is used, treatment duration is limited, and infant monitoring is in place.mayoclinic+1
Whenever possible, dosing can be timed immediately after breastfeeding to minimize peak milk concentrations, and alternative non‑pharmacological measures (hydration, diet adjustments) should be optimized before or alongside pharmacotherapy.medsafe+1

Risk modification factors

Higher infant risk is associated with prematurity, early postnatal age, comorbidities, and concurrent exposure to other sedating or gastrointestinal‑active medicines through breast milk.mayoclinic+1
Maternal factors such as hepatic or renal impairment, use of multiple medications, and prolonged or high‑dose A07 therapy increase the likelihood of elevated plasma levels and consequently higher milk concentrations.medsafe+1

Counselling points for healthcare professionals

Healthcare professionals should evaluate maternal indication, consider alternative therapies, review the specific A07 agent’s pharmacokinetic profile, and weigh the benefits of continued breastfeeding against potential infant risks.mayoclinic+1
Clear documentation of maternal therapy, infant monitoring plans, and communication with caregivers about expected outcomes and warning signs contributes to safe use of A07 medicines during lactation.medsafe+1

Information gaps and need for further data

For many individual A07 substances, high‑quality lactation pharmacokinetic and clinical safety studies are limited, and recommendations are often extrapolated from general principles and related drug classes.mayoclinic+1
Further research into milk concentrations, relative infant dose, and long‑term gastrointestinal and microbiome effects in breastfed infants would improve the precision of risk assessments for this group.medsafe+1